Inclusion Criteria:~1. Able to provide written informed consent in accordance with federal, local and
institutional guidelines. For subjects unable to provide written consent, consent will be provided by the
Person Responsible per local regulations.~2. Age ≥65 years, or ≥55 years if they have been diagnosed by a
psychiatrist or neurologist with dementia, or if they have a validated previous positive amyloid PET scan.~3.
Weight between 40 and 120 kg~4. Have an available caregiver~5. Have ≥ 6 years of education (any) and able to
follow testing instructions.~6. Have visual and auditory acuity sufficient to perform neuropsychological
testing.~7. Have prior evidence of AD pathology, by a positive amyloid assessment, or amyloid PET scan.~8.
Demonstrate abnormal memory function in the last 6 months or at screening: International Shopping List Test
(ISLT) >1.5 SD below the age adjusted mean~9. Subjective or clinical history of retrospective cognitive decline
≥6 months~10. Evidence of mild symptomatology, as defined by a screening MMSE score of ≥ 20 points~11. Meet
National Institute on Ageing/Alzheimer's Association Diagnostic Guidelines for Alzheimer's Disease (NIAAA)
research criteria for mAD or pAD~12. If receiving medication for symptomatic AD, have a stable dosing regimen
for 3 months prior to screening.~13. Females of Child Bearing Potential (FCBP) must have confirmed negative
serum pregnancy test within the 21 days prior to randomization.~14. FCBP and male subjects who are sexually
active with FCBP must agree to use highly effective contraception during the study and until 90 days after the
last dose of treatment (for sexually active male participants whose partners are FCBP) or until 30 days after
the last dose of treatment (for women of childbearing potential participants).~
